Chrysomycin A Inhibits the Proliferation, Migration and Invasion of U251 and U87-MG Glioblastoma Cells to Exert Its Anti-Cancer Effects

  • Molecules. 2022 Sep 20;27(19):6148. doi: 10.3390/molecules27196148.
Dong-Ni Liu  1 Man Liu  1 Shan-Shan Zhang  1 Yu-Fu Shang  1 Fu-Hang Song  2 Hua-Wei Zhang  3 Guan-Hua Du  1 Yue-Hua Wang  1
Affiliations
  • 1. Beijing Key Laboratory of Drug Target Identification and New Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
  • 2. School of Light Industry, Beijing Technology and Business University, Beijing 100048, China.
  • 3. School of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.
Abstract

Chrysomycin A (Chr-A), an Antibiotic from Streptomyces, is reported to have anti-tumor and anti-tuberculous activities, but its anti-glioblastoma activity and possible mechanism are not clear. Therefore, the current study was to investigate the mechanism of Chr-A against glioblastoma using U251 and U87-MG human cells. CCK8 assays, EdU-DNA synthesis assays and LDH assays were carried out to detect cell viability, proliferation and cytotoxicity of U251 and U87-MG cells, respectively. Transwell assays were performed to detect the invasion and migration abilities of glioblastoma cells. Western blot was used to validate the potential proteins. Chr-A treatment significantly inhibited the growth of glioblastoma cells and weakened the ability of cell migration and invasion by down regulating the expression of slug, MMP2 and MMP9. Furthermore, Chr-A also down regulated Akt, p-Akt, GSK-3β, p-GSK-3β and their downstream proteins, such as β-catenin and c-Myc in human glioblastoma cells. In conclusion, Chr-A may inhibit the proliferation, migration and invasion of glioblastoma cells through the Akt/GSK-3β/β-catenin signaling pathway.

Keywords
U251 glioblastoma cell; U87-MG glioblastoma cell; chrysomycin A; glioblastoma.
Products